203 related articles for article (PubMed ID: 18981293)
1. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.
Young RM; Hardy IR; Clarke RL; Lundy N; Pine P; Turner BC; Potter TA; Refaeli Y
Blood; 2009 Mar; 113(11):2508-16. PubMed ID: 18981293
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
3. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
4. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
5. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
6. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
7. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
Gururajan M; Dasu T; Shahidain S; Jennings CD; Robertson DA; Rangnekar VM; Bondada S
J Immunol; 2007 Jan; 178(1):111-21. PubMed ID: 17182546
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
9. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
10. Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells.
Miller AL; Zhang C; Shokat KM; Lowell CA
J Immunol; 2009 Jan; 182(2):988-98. PubMed ID: 19124742
[TBL] [Abstract][Full Text] [Related]
11. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
12. Nonredundant roles of Src-family kinases and Syk in the initiation of B-cell antigen receptor signaling.
Stepanek O; Draber P; Drobek A; Horejsi V; Brdicka T
J Immunol; 2013 Feb; 190(4):1807-18. PubMed ID: 23335753
[TBL] [Abstract][Full Text] [Related]
13. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of Syk in autoimmune diabetes.
Colonna L; Catalano G; Chew C; D'Agati V; Thomas JW; Wong FS; Schmitz J; Masuda ES; Reizis B; Tarakhovsky A; Clynes R
J Immunol; 2010 Aug; 185(3):1532-43. PubMed ID: 20601600
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines.
Wilcox RA; Sun DX; Novak A; Dogan A; Ansell SM; Feldman AL
Leukemia; 2010 Jan; 24(1):229-32. PubMed ID: 19776763
[No Abstract] [Full Text] [Related]
16. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
17. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
Kim SW; Rai D; McKeller MR; Aguiar RC
Blood; 2009 Jun; 113(24):6153-60. PubMed ID: 19369227
[TBL] [Abstract][Full Text] [Related]
18. Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk.
Bach MP; Hug E; Werner M; Holch J; Sprissler C; Pechloff K; Zirlik K; Zeiser R; Dierks C; Ruland J; Jumaa H
J Immunol; 2014 Feb; 192(3):1024-33. PubMed ID: 24376268
[TBL] [Abstract][Full Text] [Related]
19. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.
Hsueh RC; Hammill AM; Lee JA; Uhr JW; Scheuermann RH
BMC Immunol; 2002 Dec; 3():16. PubMed ID: 12470302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
